Back
Top 0.3%
22.8%
#1
12.1%
Top 1%
8.0%
#1
8.0%
Top 3%
6.6%
Top 75%
6.1%
Top 22%
5.2%
Top 1.0%
4.0%
Top 65%
4.0%
Top 46%
2.2%
Top 2%
2.0%
Top 13%
1.6%
Top 0.6%
1.4%
Top 2%
0.7%
Top 6%
0.7%
Top 4%
0.7%
Top 33%
0.7%
Top 24%
0.5%
A Randomised, Multi-centre Phase II Trial of Weekly Paclitaxel and Vistusertib in Platinum-Resistant Ovarian High-Grade Serous Carcinoma: OCTOPUS Arm 1
2022-05-26
oncology
Title + abstract only
View on medRxiv
Show abstract
BackgroundPreclinical studies support targeting PI3K/AKT/mTOR signalling in platinum-resistant ovarian cancer (PROC). A phase I study of the dual mTORC1/mTORC2 inhibitor vistusertib with weekly paclitaxel (wP) showed activity. We report the results of Arm 1 of OCTOPUS, the first randomised trial of weekly paclitaxel and dual mTORC1/2 inhibition in ovarian cancer. MethodsPatients with platinum-resistant or refractory high grade serous carcinoma were randomised (1:1) to wP (80mg/m2 D1,8,15 of 28 ...
Predicted journal destinations
1
Cancers
57 training papers
2
Clinical Cancer Research
22 training papers
3
Frontiers in Oncology
34 training papers
4
British Journal of Cancer
22 training papers
5
eLife
262 training papers
6
PLOS ONE
1737 training papers
7
Nature Communications
483 training papers
8
Cancer Medicine
17 training papers
9
Scientific Reports
701 training papers
10
BMJ Open
553 training papers
11
BMC Cancer
21 training papers
12
JAMA Network Open
125 training papers
13
Cell Reports
25 training papers
14
International Journal of Cancer
18 training papers
15
Journal of Clinical Investigation
50 training papers
16
Journal of Medical Genetics
22 training papers
17
BMC Medicine
155 training papers
18
Proceedings of the National Academy of Sciences
100 training papers